Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8349013 | 0.80 | TSHR (0.45) | TSHRALDH1A1RAB9AKDM4EAPOBEC3A | |
| SCHEMBL2961735 | 0.80 | TSHR (0.45) | TSHRALDH1A1RAB9AKDM4EAPOBEC3A | |
| SCHEMBL6272123 | 0.79 | ALDH1A1 (0.50) | TSHRALDH1A1RAB9AKDM4EAPOBEC3A | |
| SCHEMBL21198813 | 0.78 | ALDH1A1 (0.39) | TSHRALDH1A1RAB9AKDM4EAPOBEC3A | |
| SCHEMBL14279409 | 0.76 | MAPT (0.66) | TSHRALDH1A1RAB9AKDM4ELMNA | |
| SCHEMBL2834883 | 0.76 | MAPT (0.66) | TSHRALDH1A1RAB9AKDM4ELMNA | |
| SCHEMBL14346024 | 0.76 | TSHR (0.45) | TSHRALDH1A1RAB9AKDM4EAPOBEC3A | |
| SCHEMBL7899013 | 0.76 | MAPT (0.66) | TSHRALDH1A1RAB9AKDM4ELMNA | |
| SCHEMBL31422587 | 0.76 | MAPT (0.66) | TSHRALDH1A1RAB9AKDM4ELMNA | |
| SCHEMBL8815170 | 0.75 | MAPT (0.42) | TSHRALDH1A1RAB9AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793781-B2 | Autoimmune disorder treatment using RXR agonists | Io Therapeutics, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-10039731-B2 | Treatment of cancer with specific RXR agonists | Io Therapeutics, Inc. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10034845-B2 | Autoimmune disorder treatment using RXR agonists | lo Therapeutics, Inc. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180116985-A1 | AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-03 | — | — | US | disclosed |
| US-20170281576-A1 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS | Io Therapeutics, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-20170281577-A1 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS | Io Therapeutics, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9717702-B2 | Treatment of cancer with specific RXR agonists | Io Therapeutics, Inc. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717702-B2 | Treatment of cancer with specific RXR agonists | Io Therapeutics, Inc. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9655872-B2 | Treatment of cancer with specific RXR agonists | Io Therapeutics, Inc. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655872-B2 | Treatment of cancer with specific RXR agonists | Io Therapeutics, Inc. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160120827-A1 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS | Io Therapeutics, Inc. | 2016-05-05 | — | — | US | disclosed |
| US-9308186-B2 | Treatment of cancer with specific RXR agonists | Io Therapeutics, Inc. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150342917-A1 | Autoimmune Disorder Treatment Using RXR Agonists | Io Therapeutics, Inc. | 2015-12-03 | — | — | US | disclosed |
| US-20150196517-A1 | Autoimmune Disorder Treatment Using RXR Agonists | Io Therapeutics, Inc. | 2015-07-16 | — | — | US | disclosed |
| US-20130190395-A1 | AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS | DARTMOUTH COLLEGE (US) | 2013-07-25 | — | — | US | disclosed |
| US-20120094956-A1 | Treatment of Cancer with Specific RXR Agonists | Io Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| US-8101662-B2 | Treatment of cancer with specific RXR agonists | Io Therapeutics, Inc. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101662-B2 | Treatment of cancer with specific RXR agonists | Io Therapeutics, Inc. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080300312-A1 | Treatment of cancer with specific RXR agonists | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300312-A1 | Treatment of cancer with specific RXR agonists | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094956-A1 | Treatment of Cancer with Specific RXR Agonists | RXRA, RXRB, RXRG | TSHR 53/4885ALDH1A1 856/4885RAB9A 2309/4885 |
| US-20170281577-A1 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS | RXRA, RXRB, RXRG | TSHR 53/4885ALDH1A1 856/4885RAB9A 2309/4885 |
| US-20130190395-A1 | AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS | RXRA, RXRB, RXRG | TSHR 80/4885ALDH1A1 2346/4885RAB9A 2614/4885 |
| US-20160120827-A1 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS | RXRA, RXRB, RXRG | TSHR 53/4885ALDH1A1 856/4885RAB9A 2309/4885 |
| US-10039731-B2 | Treatment of cancer with specific RXR agonists | RXRA, RXRB, RXRG | TSHR 53/4885ALDH1A1 856/4885RAB9A 2309/4885 |
| US-20180116985-A1 | AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS | RXRA, RXRB, RXRG | TSHR 80/4885ALDH1A1 2346/4885RAB9A 2614/4885 |
| US-10034845-B2 | Autoimmune disorder treatment using RXR agonists | RXRA, RXRB, RXRG | TSHR 80/4885ALDH1A1 2346/4885RAB9A 2614/4885 |
| US-20150196517-A1 | Autoimmune Disorder Treatment Using RXR Agonists | RXRA, RXRB, RXRG | TSHR 80/4885ALDH1A1 2346/4885RAB9A 2614/4885 |
| US-20150342917-A1 | Autoimmune Disorder Treatment Using RXR Agonists | RXRA, RXRB, RXRG | TSHR 80/4885ALDH1A1 2346/4885RAB9A 2614/4885 |
| US-20080300312-A1 | Treatment of cancer with specific RXR agonists | RXRA, RXRB, RXRG | TSHR 53/4885ALDH1A1 856/4885RAB9A 2309/4885 |
| US-20170281576-A1 | TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS | RXRA, RXRB, RXRG | TSHR 53/4885ALDH1A1 856/4885RAB9A 2309/4885 |
| US-11793781-B2 | Autoimmune disorder treatment using RXR agonists | RXRA, RXRB, RXRG | TSHR 80/4885ALDH1A1 2346/4885RAB9A 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.